Navigation Links
Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
Date:2/26/2013

nical study datasets for SGX94, which is poised to enter Phase 2 clinical testing in humans.

About Soligenix, Inc.

Soligenix is a development stage biopharmaceutical company developing products to treat serious gastrointestinal diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. Soligenix is developing proprietary formulations of oral BDP (beclomethasone 17,21-dipropionate) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203), acute radiation enteritis (SGX201) and chronic Graft-versus-Host disease (orBec®), as well as developing its novel innate defense regulator (IDR) technology for the treatment of oral Mucositis (SGX942).     

Through its BioDefense Division, Soligenix is developing countermeasures pursuant to the Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan of 2011-2016 for inclusion in the US government's Strategic National Stockpile. Soligenix's lead biodefense products in development are a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin and VeloThrax™, a vaccine against anthrax exposure. RiVax™ has been shown to be well tolerated and immunogenic in two Phase 1 clinical trials in healthy volunteers. Both RiVax™ and VeloThrax™ are currently the subject of a $9.4 million National Institute of Allergy and Infectious Diseases (NIAID) grant supporting development of Soligenix's new vaccine heat stabilization technology known as ThermoVax™. Soligenix is also developing OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a $600,000 NIAID Small Business Innovation Research (SBIR) grant. OrbeShield™ has previously demonstrated statistically significant precl
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
2. Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
3. Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
4. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
5. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
6. Interleukin Genetics Reports Third Quarter 2011 Financial Results
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Pharmasset Reports Fiscal Year End 2011 Financial Results
10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
11. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Clintrax Global, Inc., ... in Raleigh, NC , recently ... as Vice President of Administration. ... all corporate processes, including their alignment with company ... Brad worked as an HR executive, specializing in ...
(Date:8/20/2014)... it that American Indians largely were wiped out by ... tuberculosis brought to the New World by European explorers., ... people lived in the Americas shortly before Europeans arrived, ... European diseases., But new research led by anthropological geneticists ... of the University of Tubingen in Germany indicates the ...
(Date:8/20/2014)... Fla. , Aug. 20, 2014 ... will host a conference call to provide an ... 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. ... 9126599 Live web cast: www.neurotropebioscience.com , under "Investor ... hours after completion through September 2, 2014 at ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group finds that the vascular ... Russia , India and ... 2013, roughly equal to the size of the United ... market will experience much faster growth as a result of strong ... Other key findings from Decision Resources Group,s coverage of the ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Neurotrope To Host Conference Call 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported ... that supports the broad anti-viral potential of the ... its PS-targeting drug bavituximab can cure lethal virus ... Bavituximab is in clinical trials for the treatment ...
... ILE ) today announced that on March ... "Exchange") notifying the Company it is not in compliance ... "Company Guide"). Specifically, the Exchange staff noted that the ... to its overall operations or its existing financial sources ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ... I/II U.K. trial of REOLYSIN(R) combined with paclitaxel/carboplatin for ... International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting ... to 22nd, 2009. The principal investigator for the trial ...
Cached Biology Technology:Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 2Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 3Isolagen, Inc. Receives Notification Letter from Amex 2Isolagen, Inc. Receives Notification Letter from Amex 3Isolagen, Inc. Receives Notification Letter from Amex 4Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial 3
(Date:8/21/2014)... team of researchers at Louisiana Tech University ... affordable, consumer-grade 3D printers and materials to ... antibacterial and chemotherapeutic compounds for targeted drug ... students and research faculty from Louisiana Tech,s ... to create filament extruders that can make ...
(Date:8/21/2014)... itself resulting in severe abdominal pain, vomiting and systemic ... are diagnosed with the disease resulting in 1000 deaths. ... to intravenous fluid and nutritional support. , Dr ... led the research, said "The major causes of pancreatitis ... alcohol intake combined with a high fat diet. In ...
(Date:8/20/2014)... CITY Researchers at Huntsman Cancer Institute (HCI) at the ... of the gene that encodes BCR-ABL, the unregulated enzyme ... to the American Cancer Society, nearly 6,000 new cases ... already in use, called tyrosine kinase inhibitors (TKIs), target ... do not cure CML but control it in a ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... symptom of physical pain or stress. But now a ... showing that tears have emotional benefits and can make ... Hasson of TAU,s Department of Zoology shows that tears ... an evolution-based mechanism to bring people closer together. ...
... by climate scientists at the University of East Anglia (UEA) ... field in the last two years. The article, ,Tipping ... Proceedings of the National Academy of Sciences in ... Paper, by Thomson Reuters. "The article captures the zeitgeist ...
... female cells counteract their double dose of X chromosomes by coating ... binds to the same X chromosome from which it is transcribed ... silencing. In the August 24, 2009 issue of the Journal ... the fact that XIST temporarily dissociates from the X chromosome during ...
Cached Biology News:Trust in a teardrop 2Tipping elements remain a 'hot' issue 2Tipping elements remain a 'hot' issue 3Aurora B answers an XIST-ential question 2
UBC13 Antibody...
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Phenytoin-BSA Isolated IgY DFc Drug...
Tropomyosin 4 [Tm4]...
Biology Products: